Advertisement

The American Society of Clinical Oncology 2017 Annual Meeting: A review and summary of selected abstracts

  • Bobbie J. Rimel
    Affiliations
    Division of Gynecologic Oncology, Cedars-Sinai, Los Angeles, CA, USA
    Search for articles by this author
  • Steven J. Gibson
    Affiliations
    Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Search for articles by this author
  • Daniele A. Sumner
    Affiliations
    Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, AZ, USA
    Search for articles by this author
  • Bradley J. Monk
    Correspondence
    Corresponding author at: Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine - Phoenix, Creighton University School of Medicine at St. Joseph's Hospital, 2222 E. Highland Ave., Suite 400, Phoenix, AZ 85016, USA.
    Affiliations
    Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, AZ, USA
    Search for articles by this author
      This year the American Society of Clinical Oncology (ASCO) Annual Meeting took place from June 2–6, 2017 again in Chicago, Illinois. The theme for this year's meeting was: Making a difference in Cancer Care with YOU. This statement set the tone for a meeting focusing on the personalization of cancer care both by biomarker driven trials and targeted therapies. It represented a celebration of the collaboration among cancer caregivers, physicians, NPs, PAs, RNs and families. Delivering on this theme, the main plenary session contained papers on a large metanalysis in colorectal cancer, phase III studies in targeted therapy for prostate cancer and breast cancer plus a novel patient reported outcome process that improved overall survival (OS) across cancer subtypes. This year's review will condense selected gynecologic cancer phase III studies presented at the meeting and include data in table form for phase II studies included in the meeting program. (Table 1, Table 2)
      Table 1Phase II trials of novel drug and cytotoxic treatment strategies in ovarian, fallopian tube, and primary peritoneal carcinomas.
      Table thumbnail t1r1
      Key: AEs = adverse events; ALT = alanine aminotransferase; An = anemia; ANC = neutropenia; ARID1A = AT-Rich Interaction Domain 1A; BRCAm = BRCA 1/2 mutation; CA-125 = cancer antigen 125; CBR = clinical benefit rate; CCOC = clear cell ovarian cancer; CMR = complete macroscopic response; CR = complete response; ct = chemotherapy; CTCs = circulating tumor cell counts; DCR = disease control rate; DVT = deep vein thrombosis; ECF = entero-cutaneous fistula; ECOG = Eastern Cooperative Oncology Group; EOC = epithelial ovarian carcinoma; ER+ = estrogen receptor positive; EVF = entero-vaginal fistula; f = fatigue; FIGO = International Federation of Gynecology and Obstetrics; FTC = fallopian tube carcinoma; Gem = gemcitabine; HDAC = histone deacetylase; HIPEC = hyperthermic intraperitoneal chemotherapy; htn = hypertension; IDS = interval debulking surgery; IHC = immunohistochemistry; KPS = Karnofsky performance score; NA(CT) = neoadjuvant (chemotherapy); OC = ovarian cancer; ORR = objective response rate; OS = overall survival; PD = progressive disease/disease progression; PDS = primary debulking surgery; PE = pulmonary embolism; PFS = progression-free survival; PLD = pegylated liposomal doxorubicin; PLTS = thrombocytopenia; PPC = primary peritoneal carcinoma; PR = partial response; PS = performance status; qd/bid = once/twice per day; qnd = every n days; qnw = every n weeks; qw/biw/tiw = once/twice/three times per week; RECIST = Response Evaluation Criteria In Solid Tumors; RFS = recurrence free survival; RR = response rate; SD = stable disease; TTFields = Tumor Treating Fields; v = vomiting
      a P/C = paclitaxel (175 mg/m2) + carboplatin (AUC 6).
      b in treatment regimen “±” substitutes “with or without”, with combination/experimental regimen being listed first vs control in results.
      c Median follow-up and PFS data will be presented after 122 events per protocol, currently at 117 events at abstract submission.
      d P/C = paclitaxel (175 mg/m2) + carboplatin (AUC 5).
      e C/Gem or C/PLD = Carboplatin (AUC4) / Gemcitabine (1000 mg/m²) or Carboplatin (AUC5)/PLD (40 mg/m²).
      f 250 mg dose if body surface area <1.65 m2.
      Table 2Phase II trials of novel agents and treatment strategies in endometrial, uterine, and cervical carcinomas.
      Table thumbnail t2
      Key: AEs = adverse events; CBR = clinical benefit rate; CC = cervical cancer; CIN = cervical intraepithelial neoplasia; CR = complete response; d = diarrhea; DCR = disease control rate; DoR = duration of response; EBRT = external beam radiotherapy; EC = endometrial cancer; ECOG = Eastern Cooperative Oncology Group; f = fatigue; FIGO = International Federation of Gynecology and Obstetrics; HDR-ICBT = high-dose rate intracavitary brachytherapy; htn = hypertension; IMRT = Intensity-modulated radiation therapy; n = nausea; ORR = overall response rate; OS = overall survival; PD = progressive disease/disease progression; PR = partial response; qnd = every n days; qnw = every n weeks; RH = radical hysterectomy; SCC = squamous cell carcinoma; SD = stable disease
      a P/C = paclitaxel (175 mg/m2) + carboplatin (AUC 6)
      b HPV16-SLP = HPV type 16 synthetic long peptides (ISA101/ISA101b); cohorts of 12 pts were vaccinated with each of 4 dose levels (20, 40, 100 and 300 μg/per peptide) of 13 overlapping HPV16-SLP covering the length of the 2 E6 and E7 proteins. Two additional cohorts of 6 pts were vaccinated with the most promising doses of 40 and 100 μg/peptide.
      c NACT consisted of cisplatin or nedaplatin
      d IMRT 50–54 Gy was delivered to the tumor and the whole uterus, and 45–48.6 Gy to the high-risk regions
      e P/C = aclitaxel (80 mg/m2), days 1, 8, 15, and 21 + carboplatin (AUC 6), 3 cycles on day 1
      f Pts with 1+ high-risk factors for recurrence including lymph vascular invasion, parametrial invasion, lymph node metastasis, or positive margin received additional 3 cycles of dose-dense paclitaxel after surgery (n = 11)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect